Medicinal product with the active ingredient rituximab - in the pharmaceutical form infusion solution concentrate (ATC: L01FA01)
Arzneimittel mit dem Wirkstoff Rituximab - in der Darreichungsform Infusionslösungskonzentrat (ATC: L01FA01)
Germany
Contract
BuyerAOK Sachsen - Anhalt
TypeSupplies
Estimated valuevalue not published
Published13 November 2024
CategoryMedical equipment & pharma · CPV 33000000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| GlaxoSmithKline GmbH & Co. KG · München | 5 | 2012–2026 |
| Novartis Pharma GmbH · Nürnberg | 5 | 2013–2026 |
| PIK AG | 5 | 2025 |
| Städtische Werke Magdeburg GmbH & Co. KG | 4 | 2025 |
| RpDoc Solutions GmbH · Saarbrücken | 4 | 2026 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
201971
202060
2021100
202287
2023169
2024277
2025392
2026161
Who knows the rhythm prepares instead of reacting.
72
days until the deadline — Friday 30 October at 22:00
How to bid
Read the full notice — Original + documents
Goes directly to this tender on Vergabemarktplatz (cosinex). The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →